IL270355A - - Google Patents

Info

Publication number
IL270355A
IL270355A IL27035519A IL27035519A IL270355A IL 270355 A IL270355 A IL 270355A IL 27035519 A IL27035519 A IL 27035519A IL 27035519 A IL27035519 A IL 27035519A IL 270355 A IL270355 A IL 270355A
Authority
IL
Israel
Application number
IL27035519A
Other languages
English (en)
Other versions
IL270355B1 (OSRAM
IL270355B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270355A publication Critical patent/IL270355A/en
Publication of IL270355B1 publication Critical patent/IL270355B1/en
Publication of IL270355B2 publication Critical patent/IL270355B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL270355A 2017-05-15 2019-10-31 Treatment of multiple sclerosis using long-acting glatiramer and stem cells derived from adipose tissue IL270355B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2017/050535 WO2018211486A1 (en) 2017-05-15 2017-05-15 Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells

Publications (3)

Publication Number Publication Date
IL270355A true IL270355A (OSRAM) 2019-12-31
IL270355B1 IL270355B1 (OSRAM) 2023-02-01
IL270355B2 IL270355B2 (en) 2023-06-01

Family

ID=64273438

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270355A IL270355B2 (en) 2017-05-15 2019-10-31 Treatment of multiple sclerosis using long-acting glatiramer and stem cells derived from adipose tissue

Country Status (8)

Country Link
US (1) US11413311B2 (OSRAM)
EP (1) EP3624815A4 (OSRAM)
JP (1) JP7000458B2 (OSRAM)
CN (1) CN110709091A (OSRAM)
AU (1) AU2017414803B2 (OSRAM)
CA (1) CA3062964C (OSRAM)
IL (1) IL270355B2 (OSRAM)
WO (1) WO2018211486A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
US11167003B2 (en) * 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
HK1054507B (zh) 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PT1592384E (pt) 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
EP1827108B1 (en) * 2004-11-29 2015-04-08 Yeda Research And Development Co., Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
KR101378874B1 (ko) 2005-10-13 2014-03-27 안트로제네시스 코포레이션 태반 줄기세포를 이용한 면역 조절
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US8021882B2 (en) 2006-08-24 2011-09-20 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
HUE036745T2 (hu) 2006-11-03 2018-07-30 Multiple Sclerosis Res Center Of New York Csontvelõ eredetû mesenchimális õssejtek, mint a neurális progenitor sejtek forrásai
WO2011041240A1 (en) 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
WO2009115581A2 (en) 2008-03-19 2009-09-24 Cryo-Save Ag Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
CA2740578A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Methods of obtaining cell populations from adipose tissue
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
EP2451943B1 (en) 2009-07-09 2016-11-23 TiGenix, S.A.U. Methods and compositions for use in cellular therapies
MX349162B (es) * 2010-01-04 2017-07-14 Mapi Pharma Ltd * Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.
US8377885B2 (en) * 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3345998B1 (en) 2010-02-18 2024-08-14 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
MX345730B (es) * 2010-12-17 2017-02-14 Anthrogenesis Corp Células adherentes derivadas del amnios (amdac) para usarse en el tratamiento de enfermedades y trastornos relacionados con el sistema inmunitario.
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
SG2014013676A (en) 2011-09-23 2014-05-29 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
CN104350146A (zh) 2012-03-12 2015-02-11 新加坡国立大学 从间充质细胞制备棕色脂肪组织(bat)
TWI642781B (zh) 2014-02-06 2018-12-01 仲恩生醫科技股份有限公司 具優異細胞保護及免疫調節之quadri-正之基質細胞
WO2015120388A1 (en) 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
US20190046576A1 (en) 2016-02-12 2019-02-14 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Also Published As

Publication number Publication date
JP2020519658A (ja) 2020-07-02
CA3062964C (en) 2024-11-12
US11413311B2 (en) 2022-08-16
CA3062964A1 (en) 2018-11-22
CN110709091A (zh) 2020-01-17
IL270355B1 (OSRAM) 2023-02-01
WO2018211486A1 (en) 2018-11-22
AU2017414803B2 (en) 2025-02-13
EP3624815A1 (en) 2020-03-25
EP3624815A4 (en) 2021-01-20
US20200147141A1 (en) 2020-05-14
JP7000458B2 (ja) 2022-02-10
IL270355B2 (en) 2023-06-01
AU2017414803A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
BR122021024397A2 (OSRAM)
BR112020006084A8 (OSRAM)
BR112019008823A2 (OSRAM)
BR122022025811B8 (OSRAM)
BR202018014992U2 (OSRAM)
BR122021023687A2 (OSRAM)
BR122021014832A2 (OSRAM)
BR122022003518A2 (OSRAM)
BR112020008820A2 (OSRAM)
BR202017025154U2 (OSRAM)
BR102017023327A2 (OSRAM)
BR202017021228U2 (OSRAM)
BR202017020981U2 (OSRAM)
BR202017017068U2 (OSRAM)
BR202017016984U2 (OSRAM)
BR202017016924U2 (OSRAM)
BR102017015495A2 (OSRAM)
BR102017015250A2 (OSRAM)
BR102017014430A2 (OSRAM)
BR202017012548U2 (OSRAM)
BR202017011220U2 (OSRAM)
BR202017010814U2 (OSRAM)
BR202017010373U2 (OSRAM)
BR202017009870U2 (OSRAM)
BR202017006953U2 (OSRAM)